ProCE Banner Activity

Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Podcast Episodes

In this podcast, an advanced practice provider discusses the latest guidance on integrating CDK4/6 inhibitors into treatment of early-stage and metastatic HR+/HER2- breast cancer. Cases from her practice illustrate how to approach treatment selection and manage important adverse events.

Released: June 30, 2022

Expiration: June 29, 2023

Begin Activity



Julia LaBarbera

Julia LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California


This activity is supported by an educational grant from Lilly.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses


Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Biotheranostics, MJH Life Sciences.



Additional Information

Program Medium

This program has been made available online.